Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBody aches and muscle discomfort are reported by some people during the early weeks of Mounjaro (tirzepatide) treatment, most often after starting or following a dose step-up. They tend to be mild, settle within days, and are linked to the same physiological adjustment that produces nausea and fatigue in some patients. Mounjaro is a prescription-only medicine; a prescriber assesses your suitability before any treatment begins. This page explains what causes musculoskeletal discomfort on tirzepatide, how to tell ordinary adjustment from something that needs attention, and when to seek medical help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When tirzepatide is introduced, or when the dose increases, your body adapts to a new hormonal signal. The medicine activates both GLP-1 and GIP receptors, slowing gastric emptying and shifting energy regulation. That process is mostly gastrointestinal, but some people also notice a general flu-like heaviness, tired limbs, a dull ache across the shoulders or back, occasional joint stiffness. This is different from acute pain; it is diffuse, tends to peak in the first day or two after an injection and then fades.
The NHS patient information for tirzepatide lists fatigue and musculoskeletal discomfort among the side effects that some people experience, alongside the more widely known nausea and digestive symptoms. Knowing that these sensations have a physiological explanation (and a predictable timing) usually makes them easier to manage. Most people find the pattern repeats less severely with each subsequent injection at the same dose level.
A common question our prescribers hear is whether the aching means the medicine is "working too hard". It does not. The discomfort is a tolerance response, not a measure of efficacy. If your injections happen to fall on Mondays and you feel achy by Tuesday, planning lighter activity that day is entirely reasonable.
Not every pain during Mounjaro treatment is an adjustment symptom. There are specific signals that sit outside the expected profile and should be assessed promptly.
Severe stomach pain is the most important one. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines highlighted acute pancreatitis as an infrequent but potentially serious side effect: a persistent, severe pain in the upper abdomen that reaches into the back, sometimes accompanied by vomiting. That symptom is not the same as ordinary muscle aching or mild nausea, and it warrants same-day medical contact.
Gallbladder problems (upper-right abdominal pain, particularly after eating fatty foods, sometimes with fever or jaundice) are also listed in the Mounjaro prescribing information. Severe muscle pain that is localised, worsening over days rather than improving, or accompanied by dark urine should similarly be assessed by a clinician rather than managed at home. If you want a more complete reference, our page covering five Mounjaro side effects that patients most commonly ask about goes into this broader picture in detail.
For the kind of diffuse aching that arrives with a new dose and resolves within a couple of days, there are straightforward ways to reduce its impact.
Hydration matters more than most people expect. GI side effects (nausea, loose stools) reduce fluid intake without you noticing, and dehydration amplifies the sense of fatigue and generalised achiness. Sipping water steadily through the day, rather than trying to catch up in the evening, makes a practical difference.
Gentle movement helps. A short walk or light stretching on the day after injection tends to ease stiff, achy muscles better than complete rest. Avoid vigorous training on the day the adjustment symptoms peak, then resume as normal once they settle.
Over-the-counter pain relief (paracetamol taken as directed) is appropriate for mild muscle discomfort. Your prescriber or the Patient Information Leaflet that comes with your pen can advise on any interactions with medicines you already take. If you find the aching is significant at every injection, that is worth discussing at your next clinical review; dose-timing adjustments or the pace of titration can sometimes help. Our prescribers are available to discuss this as part of ongoing aftercare. You can also read about headaches on Mounjaro, as this is a related adjustment symptom that often appears at the same time, and if you are wondering whether headaches are a side effect of Mounjaro, our dedicated page covers that question in detail alongside the broader picture of Mounjaro side effects that patients commonly encounter during treatment.
Stop and seek medical attention) call 111, attend an urgent care centre or call 999 in an emergency, if you experience any of the following while taking Mounjaro:
Severe abdominal pain radiating to the back (possible pancreatitis); upper-right abdominal pain with fever or yellowing of the skin or eyes (gallbladder or liver problem); signs of a serious allergic reaction such as swelling of the face, lips or throat, difficulty breathing or a rapid, spreading rash; dehydration from persistent vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down); or any unexpected, severe muscle pain that does not fit the post-injection pattern described above.
For side effects that are unexpected or troubling but not emergencies, the right channel in the UK is the MHRA's Yellow Card scheme. Reporting there helps the regulator track the real-world safety profile of newer medicines, including tirzepatide, which carries a Black Triangle (▼) status indicating it is still under active MHRA monitoring. You do not need a doctor to make a report, patients can do it directly. If you are unsure whether a symptom is worth reporting, it is. The scheme is designed precisely for that uncertainty.
For a broader look at the evidence behind tirzepatide and how it is used, the Mounjaro treatment page and our FAQs are good starting points. Some people also find it helpful to read about what it means when Mounjaro causes no side effects at all, as this is a question that comes up regularly in clinical reviews. If you have concerns at any point, our team is reachable through the contact page, seven days a week.
If you are considering treatment and want to understand how our prescribers approach side-effect management from the outset, start your free consultation and raise it there, it is exactly the kind of question a clinical review is for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.